Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield

Abbott Laboratories (ABT) delivered a strong quarter, with reported revenue up 7.4% (7.5% ex-COVID) and adjusted EPS increasing 10.5% to $1.26, complemented by 100 basis points of margin expansion. Despite this robust performance and solid guidance, the stock experienced July pressure as its outlook did not surpass market expectations. Nevertheless, the company's long-term investment case remains strong, underpinned by robust fundamentals including significant capital returns via a 50-year dividend growth streak (1.8% yield, 10% CAGR) and ongoing share repurchases, a healthy pipeline, and sufficient cash flow, which analysts affirm with "Moderate Buy" ratings and rising price targets.

Analysis

Abbott Laboratories (ABT) delivered a fundamentally strong quarter, characterized by a 7.4% year-over-year revenue increase, surpassing consensus by 70 basis points, and a leveraged 10.5% growth in adjusted earnings to $1.26. This performance was driven by robust, industry-leading growth of 12% in its Medical Devices segment, which successfully offset weakness in Diagnostics tied to declining COVID-19 testing revenue. Furthermore, the company demonstrated operational efficiency with a 100-basis-point expansion in adjusted gross and operating margins. Despite these positive results, the stock experienced a pullback as its forward guidance, while solid at 7.5% to 8% projected revenue growth, only met rather than exceeded market expectations, failing to provide a catalyst for speculators. The long-term investment thesis remains intact, supported by a durable capital return program, including a 1.8% dividend yield from a Dividend King with a 10% CAGR and a payout ratio below 50%, alongside consistent share repurchases. This is reinforced by a supportive analyst community, which holds a "Moderate Buy" rating and a consensus price target suggesting over 15% upside.

Key Decisions for Investors

• The stock's price weakness, a reaction to guidance that only met consensus rather than exceeding it, may present a compelling entry point for long-term investors prioritizing fundamental strength and capital returns over short-term momentum.
• Investors should monitor the Medical Devices segment to ensure it sustains its double-digit growth trajectory, which is the primary engine for top-line expansion, and watch for continued organic stabilization in the Diagnostics segment ex-COVID.
• The investment thesis is heavily anchored in shareholder returns; therefore, confirmation of the company's ability to maintain its dividend growth near its 10% CAGR and continue its share repurchase program is critical.
• Given the market's muted reaction to strong results, portfolio managers should consider whether high expectations are already priced in, potentially requiring a significant future guidance beat to drive the stock toward its average price target of $144.79.